CA2123588A1 - Methode de diagnostic et de traitement du cancer - Google Patents

Methode de diagnostic et de traitement du cancer

Info

Publication number
CA2123588A1
CA2123588A1 CA002123588A CA2123588A CA2123588A1 CA 2123588 A1 CA2123588 A1 CA 2123588A1 CA 002123588 A CA002123588 A CA 002123588A CA 2123588 A CA2123588 A CA 2123588A CA 2123588 A1 CA2123588 A1 CA 2123588A1
Authority
CA
Canada
Prior art keywords
growth factor
conjugate
cancer
animal
administering
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002123588A
Other languages
English (en)
Inventor
Frederick C. Leung
Darrell R. Fisher
Michael R. Thompson
Scott D. Harvey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Battelle Memorial Institute Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2123588A1 publication Critical patent/CA2123588A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CA002123588A 1991-11-14 1992-11-16 Methode de diagnostic et de traitement du cancer Abandoned CA2123588A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79218191A 1991-11-14 1991-11-14
US07/792,181 1991-11-14
PCT/US1992/009874 WO1993009816A1 (fr) 1991-11-14 1992-11-16 Procede de diagnostic et de traitement du cancer

Publications (1)

Publication Number Publication Date
CA2123588A1 true CA2123588A1 (fr) 1993-05-27

Family

ID=25156052

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002123588A Abandoned CA2123588A1 (fr) 1991-11-14 1992-11-16 Methode de diagnostic et de traitement du cancer

Country Status (5)

Country Link
EP (1) EP0614377A1 (fr)
JP (1) JPH07501332A (fr)
AU (1) AU3177893A (fr)
CA (1) CA2123588A1 (fr)
WO (1) WO1993009816A1 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179990A1 (fr) * 1994-01-12 1995-07-20 Gary Robert Bower Agents biologiques de ciblage
NO310544B1 (no) * 1999-01-04 2001-07-23 Algeta As Opparbeidelse og anvendelse av radium-223 til fremstilling av preparat samt kit til behandling av kalsifisert vev for palliasjon, benkreft-terapi og/eller overflatebehandling av ben
RU2007131538A (ru) * 2005-02-22 2009-03-27 Джи-И Хелткер Лимитед (GB) Радиоактивно меченые комплексы галлия, способы синтеза и применение для визуализации путем позитронно-эмиссионной томографии (пэт) экспресии рецептора эпидермального фактора роста (egfr) в злокачественных опухолях
US20100316639A1 (en) 2009-06-16 2010-12-16 Genentech, Inc. Biomarkers for igf-1r inhibitor therapy
GB201007354D0 (en) * 2010-04-30 2010-06-16 Algeta Asa Method
EP3442595A1 (fr) * 2016-04-14 2019-02-20 Polytherics Limited Conjugués et réactifs de conjugaison comprenant un lieur qui comprend au moins deux motifs (-ch2-ch2-o-) dans un cycle
AU2019243560A1 (en) 2018-03-26 2020-12-10 Triumf Systems, apparatus and methods for separating actinium, radium, and thorium

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5037630A (en) * 1985-01-14 1991-08-06 Neorx Corporation Metal radionuclide labeled proteins for diagnosis and therapy
US5059541A (en) * 1988-04-29 1991-10-22 Neorx Corporation Minimal derivatization of proteins
US4988496A (en) * 1988-05-31 1991-01-29 Neorx Corporation Metal radionuclide chelating compounds for improved chelation kinetics
US5135736A (en) * 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
ATE120374T1 (de) * 1989-07-20 1995-04-15 Sandoz Ag Markierte polypeptidderivate.

Also Published As

Publication number Publication date
JPH07501332A (ja) 1995-02-09
AU3177893A (en) 1993-06-15
EP0614377A1 (fr) 1994-09-14
WO1993009816A1 (fr) 1993-05-27

Similar Documents

Publication Publication Date Title
Goodwin et al. Pre-targeted immunoscintigraphy of murine tumors with indium-111-labeled bifunctional haptens
FI81263C (fi) Foerfarande foer maerkning av en maolsoekande biologiskt aktiv molekyl och metalltionein.
US4454106A (en) Use of metal chelate conjugated monoclonal antibodies
Guo et al. 99mTc-HYNIC-folate: a novel receptor-based targeted radiopharmaceutical for tumor imaging
US5194594A (en) Modified antibodies
US5679318A (en) Stable therapeutic radionuclide compositions and methods for preparation thereof
EP2311500B1 (fr) Marquage d'agents de ciblage avec gallium-68 et gallium-97
Hadley et al. Astatine-211 labeling of an antimelanoma antibody and its Fab fragment using N-succinimidyl p-[211At] astatobenzoate: comparisons in vivo with the p-[125I] iodobenzoyl conjugate
DeRiemer et al. BLEDTA: tumor localization by a bleomycin analog containing a metal-chelating group
JPH03500419A (ja) 多特異抗白血球結合体及び哺乳動物用非経口的注射剤
DE69535094T2 (de) Proteinmarkierung mit radioaktivem phospor und gezielte radiotherapie
JP2012131808A (ja) 減少した正味の正電荷を有する抗体
Khawli et al. Improved tumor localization and radioimaging with chemically modified monoclonal antibodies
CA2123588A1 (fr) Methode de diagnostic et de traitement du cancer
Ali et al. Synthesis and radioiodinationof tyramine cellobiose for labeling monoclonal antibodies
EP0380542B1 (fr) Procede de traitement de malignite et de troubles d'auto-immunite chez les etres humains
US3957963A (en) Radioiodinated bleomycin
Halpern The advantages and limits of indium-111 labeling of antibodies experimental studies and clinical applications
Day et al. The localization of radioantibodies in human brain tumors. III Radioiodination of pre-purified localizing antibody
Haisma et al. Human IgM monoclonal antibody 16.88: pharmacokinetics and distribution in mouse and man.
Searle et al. Radioimmunolocalisation of tumours by external scintigraphy after administration of 131I antibody to carcinoembryonic antigen
WO1991004057A1 (fr) Compositions de radionuclides therapeutiques stables et leurs procedes de preparation
Perkins et al. A role for gamma scintigraphy in cancer immunology and immunotherapy
Adelstein et al. Development and radiotherapeutic application of 211 At-labeled radiopharmaceuticals. Progress report, March 1, 1981-February 28, 1982
Del Vecchio et al. Endobronchial administration of iodine-131 B72. 3 monoclonal antibody in patients with lung cancer

Legal Events

Date Code Title Description
FZDE Dead